Browse studies

Find your next paid study

29 recruiting studies matching your filters

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan a…

Allogeneic Hematopoietic Stem Cell TransplantationAllogeneic Stem Cell TransplantationHematologic Malignancies

Estimated

~$10 – $6,250

University of California, IrvineNCT06028828

Phase 1

A Phase 1, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepati…

Advanced Solid TumorsHematologic Malignancies

Estimated

~$10 – $8,750

Acrotech Biopharma Inc.NCT07036133

Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Estimated

~$10 – $6,250

Milton S. Hershey Medical CenterNCT06926595

Phase 2

Optimized CBT for Pts With High-risk Hematologic Malignancies Who Have Relapsed After First ASCT

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control hig…

Hematologic Malignancies

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06807606

Phase 1

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Hematologic Malignancies

Estimated

~$10 – $8,750

Ascentage Pharma Group Inc.NCT03537482